482 related articles for article (PubMed ID: 29584730)
1. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.
Guedj J; Piorkowski G; Jacquot F; Madelain V; Nguyen THT; Rodallec A; Gunther S; Carbonnelle C; Mentré F; Raoul H; de Lamballerie X
PLoS Med; 2018 Mar; 15(3):e1002535. PubMed ID: 29584730
[TBL] [Abstract][Full Text] [Related]
2. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Chanfreau Munoz V; Doumbouya L; Souley Harouna ; Kighoma PM; Koundouno FR; Réné Lolamou ; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Gasasira Uwamahoro M; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; Barte de Sainte Fare E; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Allaford Duverger T; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D;
PLoS Med; 2016 Mar; 13(3):e1001967. PubMed ID: 26930627
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus.
Bixler SL; Bocan TM; Wells J; Wetzel KS; Van Tongeren SA; Dong L; Garza NL; Donnelly G; Cazares LH; Nuss J; Soloveva V; Koistinen KA; Welch L; Epstein C; Liang LF; Giesing D; Lenk R; Bavari S; Warren TK
Antiviral Res; 2018 Mar; 151():97-104. PubMed ID: 29289666
[TBL] [Abstract][Full Text] [Related]
4. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.
Nguyen TH; Guedj J; Anglaret X; Laouénan C; Madelain V; Taburet AM; Baize S; Sissoko D; Pastorino B; Rodallec A; Piorkowski G; Carazo S; Conde MN; Gala JL; Bore JA; Carbonnelle C; Jacquot F; Raoul H; Malvy D; de Lamballerie X; Mentré F;
PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005389. PubMed ID: 28231247
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates.
Madelain V; Duthey A; Mentré F; Jacquot F; Solas C; Lacarelle B; Vallvé A; Barron S; Barrot L; Mundweiler S; Thomas D; Carbonnelle C; Raoul H; de Lamballerie X; Guedj J
Antiviral Res; 2020 May; 177():104758. PubMed ID: 32135218
[TBL] [Abstract][Full Text] [Related]
6. Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.
Madelain V; Baize S; Jacquot F; Reynard S; Fizet A; Barron S; Solas C; Lacarelle B; Carbonnelle C; Mentré F; Raoul H; de Lamballerie X; Guedj J
Nat Commun; 2018 Oct; 9(1):4013. PubMed ID: 30275474
[TBL] [Abstract][Full Text] [Related]
7. Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.
Madelain V; Guedj J; Mentré F; Nguyen TH; Jacquot F; Oestereich L; Kadota T; Yamada K; Taburet AM; de Lamballerie X; Raoul H
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27736754
[TBL] [Abstract][Full Text] [Related]
8. Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin.
Lingas G; Rosenke K; Safronetz D; Guedj J
PLoS Comput Biol; 2021 Jan; 17(1):e1008535. PubMed ID: 33411731
[TBL] [Abstract][Full Text] [Related]
9. Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus.
Bixler SL; Bocan TM; Wells J; Wetzel KS; Van Tongeren SA; Garza NL; Donnelly G; Cazares LH; Soloveva V; Welch L; Epstein C; Liang LF; Giesing D; Lenk R; Bavari S; Warren TK
Antiviral Res; 2018 Mar; 151():50-54. PubMed ID: 29289664
[TBL] [Abstract][Full Text] [Related]
10. Ebola virus dynamics in mice treated with favipiravir.
Madelain V; Oestereich L; Graw F; Nguyen TH; de Lamballerie X; Mentré F; Günther S; Guedj J
Antiviral Res; 2015 Nov; 123():70-7. PubMed ID: 26343011
[TBL] [Abstract][Full Text] [Related]
11. Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates.
Reynard S; Gloaguen E; Baillet N; Madelain V; Guedj J; Raoul H; de Lamballerie X; Mullaert J; Baize S
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009300. PubMed ID: 33780452
[TBL] [Abstract][Full Text] [Related]
12. Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study.
Kerber R; Lorenz E; Duraffour S; Sissoko D; Rudolf M; Jaeger A; Cisse SD; Camara AM; Miranda O; Castro CM; Akoi Bore J; Raymond Koundouno F; Repits J; Afrough B; Becker-Ziaja B; Hinzmann J; Mertens M; Vitoriano I; Hugh Logue C; Böttcher JP; Pallasch E; Sachse A; Bah A; Cabeza-Cabrerizo M; Nitzsche K; Kuisma E; Michel J; Holm T; Zekeng EG; Cowley LA; Garcia-Dorival I; Hetzelt N; Baum JHJ; Portmann J; Carter L; Yenamaberhan RL; Camino A; Enkirch T; Singethan K; Meisel S; Mazzarelli A; Kosgei A; Kafetzopoulou L; Rickett NY; Patrono LV; Ghebreghiorghis L; Arnold U; Colin G; Juchet S; Marchal CL; Kolie JS; Beavogui AH; Wurr S; Bockholt S; Krumkamp R; May J; Stoecker K; Fleischmann E; Ippolito G; Carroll MW; Koivogui L; Magassouba N; Keita S; Gurry C; Drury P; Diallo B; Formenty P; Wölfel R; Di Caro A; Gabriel M; Anglaret X; Malvy D; Günther S
J Infect Dis; 2019 Jun; 220(2):195-202. PubMed ID: 30788508
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.
Oestereich L; Lüdtke A; Wurr S; Rieger T; Muñoz-Fontela C; Günther S
Antiviral Res; 2014 May; 105():17-21. PubMed ID: 24583123
[TBL] [Abstract][Full Text] [Related]
14. Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials.
Madelain V; Mentré F; Baize S; Anglaret X; Laouénan C; Oestereich L; Nguyen THT; Malvy D; Piorkowski G; Graw F; Günther S; Raoul H; de Lamballerie X; Guedj J
CPT Pharmacometrics Syst Pharmacol; 2020 May; 9(5):258-271. PubMed ID: 32198838
[TBL] [Abstract][Full Text] [Related]
15. Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis.
Escribano-Romero E; Jiménez de Oya N; Domingo E; Saiz JC
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848019
[TBL] [Abstract][Full Text] [Related]
16. Dose regimen of favipiravir for Ebola virus disease.
Mentré F; Taburet AM; Guedj J; Anglaret X; Keïta S; de Lamballerie X; Malvy D
Lancet Infect Dis; 2015 Feb; 15(2):150-1. PubMed ID: 25435054
[No Abstract] [Full Text] [Related]
17. Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014.
Bai CQ; Mu JS; Kargbo D; Song YB; Niu WK; Nie WM; Kanu A; Liu WW; Wang YP; Dafae F; Yan T; Hu Y; Deng YQ; Lu HJ; Yang F; Zhang XG; Sun Y; Cao YX; Su HX; Sun Y; Liu WS; Wang CY; Qian J; Liu L; Wang H; Tong YG; Liu ZY; Chen YS; Wang HQ; Kargbo B; Gao GF; Jiang JF
Clin Infect Dis; 2016 Nov; 63(10):1288-1294. PubMed ID: 27553371
[TBL] [Abstract][Full Text] [Related]
18. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.
Smither SJ; Eastaugh LS; Steward JA; Nelson M; Lenk RP; Lever MS
Antiviral Res; 2014 Apr; 104():153-5. PubMed ID: 24462697
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.
Delang L; Segura Guerrero N; Tas A; Quérat G; Pastorino B; Froeyen M; Dallmeier K; Jochmans D; Herdewijn P; Bello F; Snijder EJ; de Lamballerie X; Martina B; Neyts J; van Hemert MJ; Leyssen P
J Antimicrob Chemother; 2014 Oct; 69(10):2770-84. PubMed ID: 24951535
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report.
Schibler M; Vetter P; Cherpillod P; Petty TJ; Cordey S; Vieille G; Yerly S; Siegrist CA; Samii K; Dayer JA; Docquier M; Zdobnov EM; Simpson AJH; Rees PSC; Sarria FB; Gasche Y; Chappuis F; Iten A; Pittet D; Pugin J; Kaiser L
Lancet Infect Dis; 2015 Sep; 15(9):1034-1040. PubMed ID: 26201298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
